

Isotope-Labeling Studies Support an Electrophilic Compound I Iron Active Species (FeO³⁺) for the Carbon-Carbon Bond Cleavage Reaction of the Cholesterol Side Chain Cleavage Enzyme, Cytochrome P450 11A1 (P450_{scc})

Francis K. Yoshimoto,¹ I-Ji Jung,² Sandeep Goyal,³ Eric Gonzalez, and F. Peter Guengerich*

J. Am. Chem. Soc. 2016, xxx, xxxxx

Table of Contents

1. Codon optimization and construction of expression vector for human P450 11A1	S-3
2. Enzyme-catalyzed conversion of isocaproaldehyde to 4-methylpentan-1-ol (reduction rate of 5 to 10)	S-4
3. Detection of naturally abundant mono-¹⁸O-isotope incorporated ethylpyridine acetate (18d-1, <i>m/z</i> 168.0905, ~0.003%) from synthetic standard.	S-7
4. LC-MS analysis of picolinoylated 21,21,21-<i>d</i>₃-20,22-dihydroxycholesterol 3a (<i>d</i>₃:<i>d</i>₂:<i>d</i>₁:<i>d</i>₀ ratio 27:64:50:11)	S-8
5. LC-MS analysis of picolinoylated-pregnenolone using 17,21,21,21-<i>d</i>₄-20,22-dihydroxycholesterol (3b) as the starting material	S-8
6. Experimental data for synthesized chemicals	S-9
6.1. Pregnenolone-3-OTBDMS (6)	S-9
6.2. Dithiane (7)	S-10
6.3. Hg reaction (8)	S-11
6.4. Grignard adduct (9)	S-12
6.5. TBDMS deprotection (3)	S-13
6.6. Synthesis of (6a)	S-15
6.7. Deuterated dithiane (7a)	S-15
6.8. Hg reaction to form (8a)	S-18

6.9. Grignard adduct (9a)	S-19
6.10. Synthesis of (3a)	S-21
6.11. Acetonide (3z) formation	S-24
6.12. Synthesis of (5)	S-27
6.13. Synthesis of (15)	S-30
6.14. 4-Step Synthesis of 3b	S-31
6.14.1. Synthesis of (6b)	S-31
6.14.2. Synthesis of (7b)	S-32
6.14.3. Synthesis of (3b)	S-32
6.14.4. Synthesis of (3b)	S-33

1. Codon optimization and construction of expression vector for human P450

11A1. The website from Integrated DNA Technologies (Coralville, IA) (<http://www.idtdna.com/CodonOpt>) was used to generate an *Escherichia coli* codon optimization sequence for human P450 11A1 (*CYP11A1*).

A cDNA the sequence for human P450 11A1 (*CYP11A1*) and a C-terminal (His)₆ tag was synthesized and ligated into a pCW expression vector (using *NdeI* and *HindIII* restriction sites) by Genewiz (South Plainfield, NJ, USA).

The sequence used for synthesis of *CYP11A1* cDNA:

```
ATGGCAAGCACGCGCAGCCCGCGTCCGTTTAAACGAAATTCCGTCTCCAGGCGACAACGGA
M A S T R S P R P F N E I P S P G D N G
TGGCTGAATCTCTATCACTTTTGGCGTGAAACGGGCACTCATAAAGTTCACCTGCATCAC
W L N L Y H F W R E T G T H K V H L H H
GTCCAGAACTTCCAGAAGTACGGCCCTATCTACCGCGAAAAGCTGGGGAATGTTGAAAGT
V Q N F Q K Y G P I Y R E K L G N V E S
GTCTATGTCATCGATCCTGAAGATGTCGCATTGCTGTTTAAAAGTGAGGGCCCGAATCCC
V Y V I D P E D V A L L F K S E G P N P
GAACGTTTCTGATCCC GCCGTGGGTGGCTTACCACCAATATTATCAGCGTCCAATTGGC
E R F L I P P W V A Y H Q Y Y Q R P I G
GTGCTGCTGAAGAAAAGCGCAGCTTGGAAAAAGATCGCGTTGCCCTGAACCAAGAAGTC
V L L K K S A A W K K D R V A L N Q E V
ATGGCCCCAGAAGCAACCAAGAATTTCTGCCTCTGCTGGATGCCGTGTCCCGCGACTTT
M A P E A T K N F L P L L D A V S R D F
GTCTCTGTTCTGCATCGTCGATTAAGAAGGCCGGGAGCGGCAACTACAGCGGTGACATC
V S V L H R R I K K A G S G N Y S G D I
AGCGATGATCTTTTCCGTTTCCGCTTTCGAATCAATTACCAACGTTATTTTTGGTGAACGT
S D D L F R F A F E S I T N V I F G E R
CAGGGCATGCTGGAGGAAGTAGTCAACCCGGAAGCGCAACGCTTCATTGATGCAATTTAC
Q G M L E E V V N P E A Q R F I D A I Y
CAGATGTTTACACGAGCGTCCCGATGCTGAACTTACCGCCTGATCTCTTTCGCTTGTTT
Q M F H T S V P M L N L P P D L F R L F
CGTACCAAAACCTGGAAAGATCACGTTGCGGCATGGGACGTAATTTTTCAGCAAAGCCGAC
R T K T W K D H V A A W D V I F S K A D
ATCTACACTCAGAATTTCTATTGGGAGCTGCGCCAGAAAGGTAGCGTACATCAGACTAT
I Y T Q N F Y W E L R Q K G S V H H D Y
CGTGGTATTCTGTATCGCCTCCTCGGTGATAGCAAGATGAGTTTTGAGGACATTAAGCT
R G I L Y R L L G D S K M S F E D I K A
AATGTTACCGAGATGCTGGCGGGCGGTGTGGACACGACGAGCATGACTCTGCAGTGGCAT
N V T E M L A G G V D T T S M T L Q W H
TTGTACGAGATGGCGCGTAATCTGAAAGTCCAGGATATGTTACGTGCCGAAGTCCTGGCC
L Y E M A R N L K V Q D M L R A E V L A
GCCCCGTACCAAGCGCAGGGTGACATGGCAACCATGCTGCAACTGGTGCCCCTGCTGAAA
A R H Q A Q G D M A T M L Q L V P L L K
GCTAGCATCAAGGAAACGTTACGTCTGCATCCGATTAGCGTCACCTTACAGCGCTATCTG
```

A S I K E T L R L H P I S V T L Q R Y L
 GTGAACGATCTCGTGCTCCGCGACTATATGATTCCGGCGAAAACGCTGGTTCAGGTCGCG
 V N D L V L R D Y M I P A K T L V Q V A
 ATTTACGCGCTGGGGCGTGAACCGACCTTCTTTTTTCGATCCCGAAAACCTTTGACCCGACT
 I Y A L G R E P T F F F D P E N F D P T
 CGCTGGTTGAGTAAAGATAAAAAATATCACGTATTTTCGTAATCTTGGCTTCGGCTGGGGT
 R W L S K D K N I T Y F R N L G F G W G
 GTGCGCAATGCTTAGGTCGCCGTATCGCCGAACCTGGAAATGACCATTTTCCTGATTAAT
 V R Q C L G R R I A E L E M T I F L I N
 ATGCTGGAAAATTTCCGTGTTGAAATTCAGCATCTGTCTGATGTGGGTACCACCTTTAAT
 M L E N F R V E I Q H L S D V G T T F N
 CTCATTCTGATGCCGAAAAACCTATCAGCTTACCTTTTGGCCGTTCAACCAAGAAGCG
 L I L M P E K P I S F T F W P F N Q E A
 ACGCAACAACACCATCACCATCACCATTAA
 T Q Q H H H H H H STOP


2. Enzyme-Catalyzed Conversion of Isocaproaldehyde to 4-Methylpentan-1-ol.

The rate of the enzyme-catalyzed reduction of the isocaproaldehyde (4-methylpentanal) to 4-methylpentan-1-ol (NADH-dependent) was measured by using an OLIS 14 UV/Vis/NIR spectrophotometer (On-Line Instrument Systems, Bogart, GA) with a visible lamp (beam splitter on). The machine was run using OLIS Spectral Works software (Version 4.7.76) and set to 200 increments and 2 reads per datum. The reactions were run in a glass cuvette (1 cm path length) at room temperature. Two enzymes were tested: yeast and horse liver alcohol dehydrogenase (Sigma-Aldrich). Reactions were performed at room temperature.

A master mix was made containing potassium phosphate buffer (100 mM, pH 7.4) and NADH (150 μ M), which would be used for each concentration point (970 μ L of master mix was used for each concentration point). Isocaproaldehyde stock solutions were made in CH₃CN/H₂O, 1:1, v/v (100 mM, 500 mM, 1 mM, 10 mM, 50 mM, 100 mM, 150 mM, 175 mM, and 200 mM). For each concentration point, 20 μ L of substrate was added. The reactions were initiated by the addition of 10 μ L of enzyme solution (1 mg/mL) using a plumping device (cuvette mixer, to mix the solution). After the enzyme was added, the decrease in absorbance at 340 nm (i.e. the absorbance maximum of NADH) was monitored for 60-120 seconds. The molar extinction coefficient of NADH at 340 nm is 6,220 M⁻¹cm⁻¹, and the reduction rate was calculated accordingly.


Data were plotted using Prism software (Graphpad, La Jolla, CA, version 5.0d) fitting the points using the non-linear regression curve fitting option for the Michaelis-Menten equation. The k_{cat} and K_M values for yeast alcohol dehydrogenase were 4.5 s⁻¹ and 32 μ M. The k_{cat} and K_M values for horse liver alcohol dehydrogenase were 0.06 s⁻¹ and 772 μ M.

**Michaelis-Menten data:
Yeast ADH/4-methyl-pentanal**




	Enzyme Activity
Michaelis-Menten	
Best-fit values	
Vmax	4.535
Km	0.03201
Std. Error	
Vmax	0.5243
Km	0.01421
95% Confidence Intervals	
Vmax	3.411 to 5.660
Km	0.001521 to 0.06249
Goodness of Fit	
Degrees of Freedom	14
R square	0.9147
Absolute Sum of Squares	3.674
Sy.x	0.5123
Constraints	
Km	Km > 0.0
Number of points	
Analyzed	16

Horse liver alcohol dehydrogenase




	Enzyme Activity
Michaelis-Menten	
Best-fit values	
Vmax	0.05767
Km	0.7715
Std. Error	
Vmax	0.01059
Km	0.6787
95% Confidence Intervals	
Vmax	0.03458 to 0.08075
Km	0.0 to 2.250
Goodness of Fit	
Degrees of Freedom	12
R square	0.6848
Absolute Sum of Squares	0.002208
Sy.x	0.01356
Constraints	
Km	Km > 0.0
Number of points	
Analyzed	14


3. Detection of naturally abundant mono-¹⁸O-isotope incorporated ethylpyridine acetate (18d-1, *m/z* 168.0905, ~0.003%) from synthetic standard.



4. LC-MS analysis of picolinoylated 21,21,21-*d*₃-20,22-dihydroxycholesterol 3a (*d*₃:*d*₂:*d*₁:*d*₀ ratio 27:64:50:11).



The synthesis of mono-picolinoylated 21,21,21-*d*₃-20,22-dihydroxycholesterol (picolinoylated **3a**) is presented in the main text. The following *m/z* values were scanned (the location of the picolinoyl group was not verified to be the 3-position): *m/z* 527.3923, 526.3860, 525.3797, 524.3734, corresponding to *d*₃-, *d*₂-, *d*₁-, and *d*₀-mono-picolinoylated 20,22-dihydroxycholesterol. The peak of interest is at *t*_R 5.06 min.







5. LC-MS analysis of picolinoylated-pregnenolone product using 17,21,21,21- d_4 -20,22-dihydroxycholesterol (**3b**) as the starting material.


The tune conditions for detecting picolinoylated 4-methyl-pentan-1-ol were used to detect picolinoylated pregnenolone (APCI positive mode). The incubation conditions are described in the manuscript, except that a Thunberg tube, gas train, and $^{18}O_2$ were not used. The incubation was performed in a 16 × 150 mm glass test tube open to air, and the same workup procedure (including derivatization with picolinoyl chloride) described in the main text for the P450 11A1-yeast alcohol dehydrogenase assay was followed. Picolinoylated-tetradepregnenolone (**4z**, calculated: m/z 426.2941, found: m/z 426.2931, $\Delta = 2.3$ ppm) was detected by LC-MS.






6. Experimental data of synthesized chemicals


6.1. Pregnenolone-3-OTBDMS (6).




Experimental procedure for the synthesis of TBDMS ether **6**; ¹H NMR chemical shifts are reported in the main text of the manuscript. Below is the ¹H NMR spectrum (**6**, CDCl₃, 600 MHz).




6.2. Dithiane (compound 7).




Dithiane **7** was obtained following the procedure in the manuscript. Below are the ¹H and ¹³C NMR spectra (**7**, CDCl₃, 600 MHz and 150 MHz).




6.3. Hg reaction (8).




Aldehyde **8** was obtained following the procedure described in the manuscript. Below is the ¹H NMR spectrum (**8**, CDCl₃, 600 MHz).






6.4. Grignard adduct (9).




Diol **9** was obtained following the procedure in the manuscript. Below is the ^1H NMR spectrum (**9**, CDCl_3 , 600 MHz).







6.6. Synthesis of 21,21,21-*d*₃-Pregnenolone-3-OTBDMS (6a).



[21,21,21-*d*₃]-Pregnenolone-3-OTBDMS (**6a**) was obtained following the procedure in the manuscript. Below is the ¹H NMR spectrum (**6a**, CDCl₃, 600 MHz). The C21-methyl protons (δ 2.12 ppm) integrates to 0.31 while the C17-proton (δ 2.52 ppm) integrates to 0.96, confirming regioselective deuteration at C21. Below is the ¹H NMR spectrum (**6a**, CDCl₃, 600 MHz).





6.7. Deuterated dithiane (7a).




n-BuLi (3.68 mL, 2.5 M in diethyl ether, 9.2 mmol, 2.0 mol eq) was added to dithiane (1.11 g, 9.2 mmol, 2.0 mol eq) in THF (50 mL) at -78 °C. The reaction was gradually warmed to -20 °C over 1.5 hr and cooled back to -78 °C. [21,21,21-*d*₃]-Pregnenolone-3-OTBDMS (**6a**, 2.0 g, 4.6 mmol) in THF (20 mL) was added. After 2.5 h, the reaction was quenched upon addition of H₂O (100 mL). The reaction mixture was extracted with ethyl acetate (200 mL). The organic extract was concentrated with reduced pressure and

purified by flash column chromatography (100% hexanes to 50% hexanes in ethyl acetate, v/v) to yield dithiane **7a** (0.61 g, 1.1 mmol, 55%). *R_f* 0.53 of **7a** (hexanes:ethyl acetate, 4:1, v-v). ¹H NMR (600 MHz, CDCl₃) δ 5.32-5.29 (m, 1H), 4.13 (broad s, 1H), 3.51-3.43 (m, 1H), 2.97-2.92 (m, 1H), 2.90-2.79 (m, 2H), 2.29-2.22 (m, 1H), 2.19-2.12 (m, 1H), 2.12-2.04 (m, 1H), 1.99-1.93 (m, 1H), 1.92-1.76 (m, 3H), 1.75-1.67 (m, 2H), 1.67-1.60 (m, 1H), 1.57-1.38 (m, 5H), 1.25 (td, *J*₁ = 12.9 Hz, *J*₂ = 4.3 Hz, 1H), 1.21-1.12 (m, 1H), 1.06-1.01 (m, 1H), 0.99 (s, 3H), 0.93-0.89 (m, 1H), 0.88 (s, 9H), 0.87 (s, 3H), 0.46 (s, 6H); ¹³C NMR (150 MHz, CDCl₃) δ 141.7, 121.1, 72.7, 61.3, 57.0, 55.2, 50.2, 43.1, 42.9, 40.2, 37.5, 36.7, 32.2, 31.9, 31.7, 31.5, 31.0, 26.14, 26.06, 23.9, 21.8, 21.0, 19.5, 18.4, 13.5, -4.5. Following are the ¹H and ¹³C NMR spectra (compound **7a**, CDCl₃, 600 MHz), followed by DEPT90/ DEPT135/¹³C NMR stacked overlay, HSQC spectra of **7a**.







¹³C NMR spectra overlay of compounds **7** and **7a** (non-deuterated vs. deuterated, δ - 10 ppm—81 ppm) - notice the absence of the peak at δ 24.1 ppm in deuterated compound **7a** corresponding to C21:




6.8. Hg reaction to form deuterated aldehyde (**8a**).



The ratio of acetonitrile to water (100:1 or 10:1, v/v) is important for optimum yield (i.e. excess water lowers the yield of the reaction). Dithiane **7a** (0.61 g, 1.1 mmol), HgO (0.48 g, 2.2 mmol, 2.0 mol eq), HgCl₂ (0.60 g, 2.2 mmol, 2.0 mol eq) were dissolved in acetonitrile (100 mL) and water (100 mL). The reaction was stirred at reflux overnight. The mixture was filtered through a short pad of Celite. The concentrated material was purified by flash column chromatography (100% hexanes to 50% hexanes in ethyl acetate, v/v) to afford aldehyde **8a** (**8a**, 0.08 g, 0.17 mmol, 15%) as a white solid. *R_f* 0.63 of **8a** (hexanes:ethyl acetate, 4:1, v-v). ¹H NMR (600 MHz, CDCl₃) δ 9.56 (s, 1H), 5.31-5.30 (m, 1H), 3.51-3.43 (m, 1H), 3.240-3.237 (m, 1H), 2.30-2.24 (m, 1H), 2.19-2.09 (m, 2H), 2.02-1.92 (m, 1H), 1.85-1.76 (m, 1H), 1.76-1.60 (m, 4H), 1.59-1.39 (m, 7H), 1.36-1.24 (m, 3H), 1.22-1.11 (m, 1H), 1.09-1.02 (m, 2H), 1.00 (s, 3H), 0.98-0.90 (m, 1H), 0.89 (s, 12H), 0.79 (s, 3H), 0.05 (s, 6H). Below is the ¹H NMR spectrum (**8a**, CDCl₃, 600 MHz).




6.9. C21-Deuterated Grignard adduct (**9a**).




The procedure described in the manuscript to convert aldehyde **8** to diol **9** was followed to convert **8a** to **9a**. *Diol **9a** was reactive with acetone at room temperature to form the acetonide (see synthesis of **3z**). Therefore, the use of acetone to dissolve diol **9a** was avoided. R_f 0.41 of **9a** (hexanes:ethyl acetate, 4:1, v-v). ^1H NMR (600 MHz, CDCl_3) δ 5.32-5.31 (m, 1H), 3.51-3.45 (m, 1H), 3.41-3.36 (m, 1H), 2.30-2.23 (m, 1H), 2.21 (d, $J = 2.7$ Hz, 1H), 2.17 (ddd, $J_1 = 13.4$ Hz, $J_2 = 4.7$ Hz, $J_3 = 2.2$ Hz, 1H), 2.14-2.09 (m, 1H), 2.01-1.94 (m, 1H), 1.85-1.77 (m, 3H), 1.75-1.69 (m, 1H), 1.69-1.59 (m, 2H), 1.59-1.39 (m, 11H), 1.32-1.09 (m, 7H), 1.08-1.02 (m, 1H), 1.00 (s, 3H), 0.91 (d, $J = 6.9$ Hz, 1H), 0.89 (broad s, 13H), 0.88-0.84 (m, 1H), 0.56 (s, 6H); ^{13}C NMR (150 MHz, CDCl_3) δ 141.8, 121.2, 72.7, 56.9, 54.9, 50.3, 43.4, 43.0, 40.4, 37.5, 36.8, 36.5, 32.2, 32.0, 31.5, 29.3, 28.3, 26.1, 24.1, 23.1, 22.5, 22.1, 21.1, 19.6, 18.4, 13.7, 0.15, -4.4. Below are the ^1H and ^{13}C NMR spectra (**9a**, CDCl_3 , 600 and 150 MHz), HSQC, NOESY, and COSY spectra.


1 FVII-033_Grignard_CD3_tube10_04_06_2016 1 1 Y:\Users\francis Yoshimoto\Desktop\NMR_DATA
Spectrum ProcPars AcqPars Title PulseProg Peaks Integrals Sample Structure Plot Fid




1 FVII-033_Grignard_CD3_tube10_04_06_2016 2 1 Y:\Users\francis Yoshimoto\Desktop\NMR_DATA
Spectrum ProcPars AcqPars Title PulseProg Peaks Integrals Sample Structure Plot Fid




1 FVII-033_Grignard_CD3_tube10_04_06_2016 3 1 Y:\Users\francis Yoshimoto\Desktop\NMR_DATA
Spectrum ProcPars AcqPars Title PulseProg Peaks Integrals Sample Structure Plot Fid








6.10. Synthesis of 21,21,21- d_3 -3 β ,20 R ,22 R -triol (**3a**).




Beginning with **9a** (7 mg, 13 μ mol) and following the procedure in the main text for **9** to **3**, the triol **3a** was obtained (4 mg, 9.5 μ mol, 73%). Similar to diol **9a**, triol **3a** is reactive with acetone to form the 20,22-acetonide, so the use of acetone was avoided to dissolve


triol **3a**. Ethyl acetate, hexanes, methanol, and dichloromethane were solvents used with compounds **9a** and **3a**. The R_f of **3a** 0.59 (hexanes:ethyl acetate, 1:1, v-v). ^1H NMR (600 MHz, CDCl_3) δ 5.38-5.33 (m, 1H), 3.58-3.48 (m, 1H), 3.41-3.36 (m, 1H), 2.35-2.18 (m, 1H), 2.16-2.06 (m, 1H), 2.04-1.94 (m, 1H), 1.89-1.78 (m, 3H), 1.76-1.39 (m, 10H), 1.30-1.12 (m, 6H), 1.12-1.03 (m, 1H), 1.02 (s, 3H), group of singlets with 9H integration: (0.916, 0.904, 0.900, 0.893, 0.888); ^{13}C NMR (150 MHz, CDCl_3) δ 140.9, 121.7, 76.6, 71.9, 56.8, 50.2, 43.4, 42.4, 43.3, 36.7, 36.5, 31.9, 31.8, 31.4, 29.3, 28.2, 24.1, 23.1, 22.5, 21.1, 19.5, 13.7. Below are the ^1H and ^{13}C NMR spectra (**3a**, CDCl_3 , 600 and 150 MHz).



Overlay of 20R,22R-dihydroxycholesterol (**3**) and 21,21,21-*d*₃-20R,22R-dihydroxycholesterol (**3a**) in the upfield region:






6.11. Acetonide (**3z**) formation with exposure to acetone from compound **9a**.




The TBDMS-deprotection procedure to yield triol **3a** was performed, however, before purification by flash column chromatography, acetone was used to dissolve the triol (**3a**) residue to load the material on the silica gel column. The only recovered material was the acetonide (**3z**). ¹H NMR of **3z** (600 MHz, CDCl₃) δ 5.37-5.33 (m, 1H), 3.63 (dd, *J*₁ = 9.4 Hz, *J*₂ = 2.6 Hz, 1H), 3.57-3.48 (m, 1H), 2.33-2.27 (m, 1H), 2.27-2.19 (m, 1H), 2.16-2.11 (m, 1H), 2.12-2.05 (m, 1H), 2.02-1.95 (m, 1H), 1.95-1.79 (m, 3H), 1.69-1.42 (m, 13H), 1.41 (s, 3H), 1.39-1.30 (m, 2H), 1.30 (s, 3H), 1.20-1.03 (m, 5H), 1.01 (s, 3H), 0.95-0.91 (m, 1H), 0.90 (s, 3H), 0.89 (s, 3H), 0.81 (s,


3H); ^{13}C NMR (150 MHz, CDCl_3) δ 121.8, 106.7, 57.1, 50.2, 42.4, 40.2, 37.4, 36.6, 31.9, 31.8, 31.7, 31.1, 29.2, 28.4, 27.0, 26.9, 24.1, 22.9, 22.70, 22.66, 21.2, 19.6, 13.1, 0.13. Attempts to convert the acetonide back to the triol (compound **3a**) with HCl (0.5 mL, 12 M) in CH_3OH (5 mL) at room temperature for 24 h resulted in major decomposition to an unwanted compound. Following are the ^1H , ^{13}C NMR, and HSQC spectra (**3z**, CDCl_3 , 600 and 150 MHz).




6.12. Synthesis of isocaproaldehyde (5) (see main text for procedure).




Following are the ¹H and ¹³C NMR spectra (5, CDCl₃, 600 and 150 MHz).









^1H NMR spectrum of isocaproaldehyde (5**) in D_2O (potassium phosphate buffer, $\text{pD} = 7.4$, as described in the manuscript).**




The integrations of the aldehyde and *gem*-dihydroxymethine (**5** and **5-g2**) can be calculated to determine the ratio of the aldehyde and *gem*-diol (1.0:0.9) in D_2O (600 MHz). Similarly, the methyl protons (C5, δ 0.88, 0.89) can also be used to determine the same ratio. Below is the ^1H NMR spectrum (**5**, D_2O , 600 MHz) along with the expanded regions (δ 0.80-2.65 ppm and δ 4.75-5.10 ppm).




6.13. Synthesis of 4-methyl-pentan-1-ol picolinoyl ester (**15**).




Picolinoyl chloride (200 mg, 1.4 mmol) was added to a solution of 4-methyl-pentan-1-ol (100 mg, 0.98 mmol) in THF (10 mL). The reaction was stirred at room temperature for 2 hr and concentrated by reduced pressure. The crude material was purified by preparative TLC (2,000 μ M thickness of silica, 1:1 ethyl acetate:hexanes, v/v) to afford picolinoyl ester **15** as an oil (20 mg, 0.10 mmol, 10%). R_f 0.5 of compound **15** (hexanes:ethyl acetate, 1:1, v-v). ^1H NMR (600 MHz, CDCl_3) δ 8.73 (d, $J = 4.9$ Hz, 1H), 8.09 (d, $J = 7.7$ Hz, 1H), 7.81 (td, $J_1 = 7.7$ Hz, $J_2 = 1.6$ Hz, 1H), 7.44 (ddd $J_1 = 7.7$ Hz, $J_2 = 4.6$ Hz, $J_3 = 0.9$ Hz, 1H), 4.36 (t, $J = 7.1$ Hz, 1H), 1.82-1.77 (m, 2H), 1.61-1.49 (m, 2H), 1.31-1.25 (m, 2H), 0.87 (d, $J = 6.5$ Hz, 6H); ^{13}C NMR (150 MHz, CDCl_3) δ 165.3, 150.0, 148.4, 137.1, 126.9, 125.2, 66.4, 35.0, 29.3, 27.8, 26.7, 22.5. Following are the ^1H and ^{13}C NMR spectra (**15**, CDCl_3 , 600 and 150 MHz).






6.14. 4-Step Synthesis of 3b. The following reaction sequence was followed to access 17,21,21,21-d₄-20*R*,22*R*-dihydroxycholesterol (**3b**).



6.14.1. Synthesis of 17,21,21,21-d₄-pregnenolone-3-*O*-*tert*-butyldimethylsilyl ether (**6b**).

NaH (3.0 g, 125 mmol) was added to a solution of pregnenolone-3-*O*-*tert*-butyldimethylsilyl ether **6** (5.5 g, 12.8 mmol) in THF (100 mL) and D₂O (20 mL) at 0 °C. The flask was evacuated and backfilled with argon. MeOD (5 mL, 99%) was added and the reaction was stirred overnight. The reaction mixture was concentrated, and the crude material (17,21,21,21-d₄-pregnenolone-3-*O*-*tert*-butyldimethylsilyl ether, **6b**) was directly used for the next step (compound **6b** to compound **7b**). Following is the ¹H NMR spectrum of the crude material (**6b**, CDCl₃, 600 MHz).




6.14.2. Synthesis of 17,21,21,21-*d*₄-dithiane (**7b**).

n-BuLi (14.7 mL, 2.5 M, 37 mmol) was added to a solution of 1,3-dithiane (4.8 g, 40 mmol) in THF (100 mL) at -78 °C. After 1 h, **6b** (crude material from the previous step) was added in THF (50 mL) and was stirred for 1.5 h during which the reaction was warmed gradually to -20 °C. The reaction was quenched with H₂O (100 mL). The reaction mixture was extracted with ethyl acetate (250 mL) and concentrated under reduced pressure. The crude material (~2.3 g) was used directly for the next reaction.

6.14.3. Synthesis of 3-hydroxy-aldehyde (**8b**).

A mixture of HgO (1.3 g, 6.2 mmol, 1.5 mol eq), HgCl₂ (2.2 g, 8.2 mmol, 2.0 mol eq), and dithiane (2.3 g, 4.1 mmol) in acetonitrile:H₂O (150 mL:10 mL) was refluxed for 2.5 hr. The reaction mixture was filtered through a short pad of silica gel with ethyl acetate (100 mL) to remove the mercury salts. The eluent was concentrated under reduced pressure and purified by flash column chromatography (100% hexanes to 50% hexanes/ethyl acetate, v/v) to afford 3-hydroxy-aldehyde (**8b**, 1.9 g, 5.4 mmol, 42% for three steps from **6b**) as a white solid. Below is the ¹H NMR spectrum of

compound **8b** (CDCl_3 , 400 MHz).



6.14.4. Synthesis of 17,21,21,21- d_4 -20R,22R-dihydroxycholesterol (**3b**).

Isopentylmagnesium bromide (32 mL of a 2.5 M solution in diethyl ether, 82 mmol) was added to 3-hydroxyaldehyde (1.9 g, 4.09 mmol) in THF (150 mL) at -78°C . After 2 hr, the reaction was quenched with H_2O (100 mL) at -78°C and warmed to room temperature. The reaction mixture was extracted with ethyl acetate (2×150 mL). The combined organic extracts were concentrated with reduced pressure and purified by flash column chromatography (100% hexanes to 50% hexanes and ethyl acetate v/v) to afford title compound (500 mg, 1.18 mmol, 29%) as an impure mixture but contained the desired product (**3b**) from an LC-MS analysis (calculated $[\text{M}-\text{H}_2\text{O}]^+$: m/z 405.3665, found: m/z 405.3657, $\Delta = 1.9$ ppm, APCI-positive). This mixture was directly used for the incubation with P450 11A1.

